SCHEMBL708612

SCHEMBL708612

CCCCNC(=O)C1C2CN(CCC(F)(F)F)CC21

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FPR3 P25089 2/20 0.41
FPR2 P25090 2/20 0.41
MEN1 O00255 1/20 0.38
CYP2C19 P33261 1/20 0.38
KMT2A Q03164 1/20 0.38
GAA P10253 1/20 0.38
GNAI3 P08754 3/20 0.37
GNAO1 P09471 3/20 0.37
GNAI1 P63096 3/20 0.37
ALDH1A1 P00352 3/20 0.36
BCHE P06276 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EPHX1 P07099 1/20 0.36
NAAA Q02083 1/20 0.35
KDM4E B2RXH2 3/20 0.35
NPC1 O15118 1/20 0.35
PRCP P42785 1/20 0.35
USP2 O75604 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712559 0.96 FPR3 (0.43) FPR3FPR2GNAI3GNAO1GNAI1
SCHEMBL710574 0.95 GNAI3 (0.43) FPR3FPR2GNAI3GNAO1GNAI1
SCHEMBL5505986 0.83 SIGMAR1 (0.47) FPR3FPR2MEN1KMT2AALDH1A1
SCHEMBL711457 0.80 FPR3 (0.39) FPR3FPR2ALDH1A1
SCHEMBL708329 0.79 CACNA1H (0.37) FPR3FPR2
SCHEMBL15967367 0.78 CYP2C19 (0.39) FPR3FPR2CYP2C19ALDH1A1EPHX1
SCHEMBL711122 0.75 EPHX1 (0.45) FPR3FPR2KMT2AGAAEPHX1
SCHEMBL708613 0.73 GNAI3 (0.33) GNAI3GNAO1GNAI1
SCHEMBL15967264 0.71
SCHEMBL712405 0.70 MAPK1 (0.46) FPR3FPR2ALDH1A1L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 FPR3 2134/4885FPR2 2708/4885MEN1 3132/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 FPR3 2137/4885FPR2 2866/4885MEN1 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.